Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Silexion Therapeutics Corp. raised $837,366.36 through the exercise of Series E warrants. The company will use the proceeds for working capital and general corporate purposes.
Silexion Therapeutics Corp. announced the exercise of certain outstanding series E warrants. The gross proceeds from this exercise are expected to be $837,366.36. The offering is set to close on or about September 29, 2026
Company Information
Company
Silexion Therapeutics
Location
Ramat Gan, Tel Aviv District, Israel
About
Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Fundz sees it the moment Silexion Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Ramat GanBiotechnologyHealth CareTherapeuticsPharmaceutical